BRVEHealthcare
Braveheart Bio, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Braveheart Bio, Inc. (BRVE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are BRVE insiders buying or selling?
In the last 12 months, Braveheart Bio, Inc. insiders reported 10 open-market purchases ($159.0M) and 0 sales ($0) — net buying of $159.0M. Since August 2026, Trabud has recorded 10 Form 4 filings for BRVE: 10 buys ($159.0M) and 0 sells ($0).
Source: SEC EDGAR Form 4
Key Statistics (August 2026 – Aug 11, 2026)
Total Form 4 filings
10
SEC EDGAR
Insider filers
10
Insider buys (10)
$159.0M
Insider sells (0)
$0
Insider sentiment
Net buyingNet insider flow of $159.0M in net buying since August 2026, and $159.0M in net buying over the last 12 months. 10 insider buys in the last 90 days.
Recent BRVE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | AH Bio Fund IV, L.P. | 10% Owner | Purchase | 1.1M | $18.00 | $19.8M | SEC ↗ |
| Aug 11, 2026 | Erez Chimovits | Director, 10% Owner | Purchase | 1.9M | $18.00 | $34.9M | SEC ↗ |
| Aug 11, 2026 | ORBIMED ADVISORS LLC | Director, 10% Owner | Purchase | 1.9M | $18.00 | $34.9M | SEC ↗ |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | Purchase | 3.6M | $18.00 | $64.8M | SEC ↗ |
| Aug 7, 2026 | James Paul Rickey | Chief Financial Officer | Purchase | 27.8K | $18.00 | $500.0K | SEC ↗ |
| Aug 7, 2026 | Christopher Viehbacher | Director | Purchase | 83.3K | $18.00 | $1.5M | SEC ↗ |
| Aug 7, 2026 | David I Malek | Director | Purchase | 4.2K | $18.00 | $75.0K | SEC ↗ |
| Aug 7, 2026 | Michele A. Anderson | Chief Development Officer | Purchase | 1.1K | $18.00 | $20.0K | SEC ↗ |
| Aug 7, 2026 | Travis Murdoch | CEO and President | Purchase | 83.3K | $18.00 | $1.5M | SEC ↗ |
| Aug 7, 2026 | David Charles Lubner | Director | Purchase | 55.6K | $18.00 | $1000.0K | SEC ↗ |
Showing the 10 most recent of 10 Form 4 filings for Braveheart Bio, Inc..
Most active BRVE insiders
- AH Bio Fund IV, L.P.1 filing
- Christopher Viehbacher1 filing
- David Charles Lubner1 filing
- David I Malek1 filing
- Erez Chimovits1 filing
Ask anything about BRVE insider activity
Use Trabud's AI agent to query Braveheart Bio, Inc.'s Form 4 history in plain English — "Show me BRVE CEO purchases this year" or compare it against any other ticker.
Open the AI agentBRVE insider trading FAQ
Are Braveheart Bio, Inc. insiders buying or selling?
In the last 12 months, Braveheart Bio, Inc. insiders reported 10 open-market purchases ($159.0M) and 0 sales ($0) — net buying of $159.0M. Since August 2026, Trabud has recorded 10 Form 4 filings for BRVE: 10 buys ($159.0M) and 0 sells ($0). Over the full record that is net buying of $159.0M.
How many insiders trade BRVE stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Braveheart Bio, Inc.. The most recent filing was accepted on Aug 11, 2026.
Where does Trabud get BRVE insider trading data?
All BRVE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.